Skip to content
Research Article Open access CC BY 4.0

Efficacy and Side Effects of Generic (Osloda®) and Brand-Name (Xeloda®) Capecitabine in Metastatic Breast Cancer

Parastoo Hajian, Farnaz Tabatabaie, Hamidreza Mirzaei

International Research Journal of Oncology · pp. 77–83 · Published 22 Jun 2020

Abstract

Purpose: To compare the efficacy and side effects of brand-name capecitabine (Xeloda®) vs. generic (Osloda®) in metastatic breast cancer. Methods: In this non-randomized clinical trial, 39 patients with metastatic breast cancer were included and divide into Xeloda® (19 patients, mean age of 49.5 years) or Osloda® (20 patients, mean age of 51.7 years) groups. A total of six 3-week cycles (1250 mg/m2 daily) were administered. Efficacy and side effects were documented in a three-year follow-up period. Results: The four most common treatment-related adverse events did not differ significantly in Xeloda group vs. Osloda group including hand-foot syndrome (68.4% vs. 65%, P= 0.82), Anorexia (47.4% vs. 50%, P= 0.86), pain (57.9% vs. 40%; P= 0.26), and nausea (52.6% vs. 35%; P= 0.26). Most patients in both groups (25 subjects) showed partial response. Nine patients in each group died (47.4% in Xeloda group and 45% in Osloda group, P= 0.88). Mean overall survival was 20.13 months in Xeloda group and 25.82 months in Osloda group (P= 0.47). Conclusion: Xeloda and Osloda had comparable efficacy and side effects in metastatic                    breast cancer. Considering the lower cost of Osloda, this agent can be used instead of           Xeloda.

Capecitabine breast cancer metastasis adverse event side effect efficacy

Cited by 0

No indexed citations yet.

Article metrics

Real usage data collected on this platform.

0

Page views

0

PDF downloads

0

Outbound clicks

0

Citations

Views by country

Approximate, from request IP at view time — not citizenship or institution. Countries with fewer than 5 views are grouped as "Other".

No views recorded yet.

Traffic sources

Referring site, by host.

No traffic recorded yet.

Views and downloads exclude known bots/crawlers. Citations combines this platform's own DOI-resolved index with each external source's own reported total — see Cited by above for individually listed citing works. Last refreshed 0 seconds ago.